Orexia Therapeutics has an emerging pipeline of assets comprised of novel small molecules and peptides which activate orexin receptors. While our primary focus is Narcolepsy Type 1, we are also conducting research to explore the role of orexin in a broad range of therapeutic indications, to maximize the number of patients who will benefit from therapies based on orexin activation.